December 4, 2018 8:04am
Take any profit before it erodes and the market is closed on Wednesday!
Pre-open indications: 2 BUYs and 2 SELLs
News: Pluristem Therapeutics Inc. (PSTI) (PSTI.TA) has entered into a license agreement with a subsidiary of Chart Industries regarding PSTI’s “thawing device” for cell-based therapies. Per the terms of the agreement, Chart obtains the exclusive rights to manufacture and market the thawing device in all territories worldwide, excluding China, with PSTI receiving royalties from sales of the product and supply agreement. They’re off-loading technology, BUY for minimal movement in share pricing.
I answer one question, in which company should investors put, keep and commit their money!
Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector
U.S. stock index futures are diving
Dow futures are DOWN -0.44% (-114 points) and NASDAQ futures are DOWN -0.53% (-38 points)
Dow futures point to a negative open amid doubts over the US-China trade deal,
European stocks were lower, amid rising doubts over whether the world's two largest economies will be able to resolve their trade differences.
Asian markets slipped amid uncertainty about the future of U.S.-China trade relations.
Data docket: Redbook sales figures are due at 8:55 a.m. ET. Meanwhile, New York Federal Reserve President John Williams is due to give a speech on tightness in the labor market at 10 a.m. ET.
- The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -0.2% DOWNSIDE
- The SPDR S&P Biotech ETF (XBI) is NOT indicating
- The Health Care Select Sector SPDR ETF (XLV) is NOT indicating
- The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.3% DOWNSIDE
U.S. stock futures were diving after the highs of yesterday's session; caution over uncertainty is the thematic!
I am back to ... "Skim if you can trim, buy if it will fly and sell if compelled!"
Monday night’s post, “ASH defines the sector while trade initiatives explain the markets.”
Last night’s percentage (%) indicators:
- Review the range of the 32 upside from +0. % () to +% () while the 10 downside ranged from -0.44% (BLCM) to -5.20% (BLUE) with 3 flat close (AST, RENE.L and BTX).
- 11 out of the 32 upside had higher (than the 3 month average) volume
- 4 out of the 10 downside experienced greater volume (than the 3 month average).
Recounting the months:
- In 1 session in December – there was 1 positive close;
- In 22 sessions in November – there were 1 holiday, 10 positive closes, 1 neutral and 10 negative closes
- In 23 sessions in October – there were 17 negative closes and 6 positive sessions;
- In 19 sessions in September – there were 10 negative closes and 9 positive sessions;
- In 21 August sessions – 6 had negative and 15 had positive closes
Companies in my headlights – It’s your decision; I provide an idea and context:
bluebird bio, Inc. (BLUE) closed down -$6.39 to $116.50 after Friday’s -$2.25 to $122.89 but, presented data that was mostly positive, with high expectations for group C (only treated with the 'refined' LentiGlobin). However, one serious adverse event (SAE) was reported from Group A; a case of myelodysplasic syndrome that isn't believed to be therapy related but could be due to the conditioning needed for therapy. BLUE had a negative aftermarket -$0.50 or -0.43% - BUY to SELL;
Global Blood Therapeutics (GBT) closed up +$15.08 to $46.62 and has a negative -$0.61 or -1.31% aftermarket indication. Traders will be selling into the upside – BUY to SELL;
Verastem Oncology (VSTM) closed up +$0.11 to $5.21 but, has a negative -$0.06 or -1.15% aftermarket indication. VSTM’s erratic share performance is a liability to any upside. November saw a low of $4.79 and a high of $5.85 having started the month at $5.18. VSTM presented data demonstrating that the combination of oral duvelisib and romidepsin has an … “acceptable safety profile” and the presence of early signals of anti-lymphoma activity in patients with peripheral T-cell lymphoma (PTCL) - NO WOWs – today, seven posters highlight new and updated clinical and pre-clinical data from its duvelisib development program - SELL;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.